eISSN: 1731-2531
ISSN: 1642-5758
Anaesthesiology Intensive Therapy
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

 
4/2020
vol. 52
 
Share:
Share:
more
 
 
abstract:
Original paper

Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients – new assessment

Dariusz Onichimowski
1, 2
,
Joanna Wolska
1, 2
,
Hubert Ziółkowski
3
,
Krzysztof Nosek
2, 4
,
Jerzy Jaroszewski
3
,
Mirosław Czuczwar
5

1.
Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland
2.
Clinical Department of Anaesthesiology and Intensive Care, Regional Specialist Hospital in Olsztyn, Poland
3.
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Olsztyn, Poland
4.
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Warmia and Mazury, Olsztyn, Poland
5.
2nd Department of Anaesthesiology and Intensive Therapy, Medical University of Lublin, Poland
Anaesthesiol Intensive Ther 2020; 52, 4: 267–273
Online publish date: 2020/10/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The first studies on the pharmacokinetics of ciprofloxacin during continuous renal replacement therapy were conducted using filters with a relatively small surface area and with lower intensity of the procedure than nowadays. The aim of this study was to assess the pharmacokinetics and the probability of achieving pharmacokinetic/pharmacodynamic (PK/PD) target for ciprofloxacin during renal replacement therapy using a filter with large surface area and higher intensity.

Material and methods
Eighteen patients were considered eligible for treatment with ciprofloxacin (400 mg every eight hours intravenously) during continuous renal replacement therapy. Blood samples were collected from the arterial line of the renal replacement circuit before (time 0) and after 30, 60, 75, 90, 120, 180, 240, and 480 minutes following the initiation of ciprofloxacin infusion. Ciprofloxacin concentrations in the collected samples were determined using fully validated liquid chromatography. The pharmacokinetic analysis was performed using non-compartmental analysis. The measure adopted to assess the efficacy of the antibiotic therapy was the proportion of patients for whom pre-defined PK/PD indices were achieved.

Results
There was a considerable inter-individual variability observed in pharmacokinetic parameters for ciprofloxacin. 100% of patients achieved PK/PD target AUC0–24/MIC > 40, AUC0–24/MIC > 125, AUC0–24/MIC > 250 for MIC 1, 0.25, and 0.125 µg mL-1, respectively.

Conclusions
High doses of ciprofloxacin (400 mg every eight hours intravenously) during continuous renal replacement therapy should be used to maximally increase the proportion of patients in whom clinical efficacy, expressed as achieving the PK/PD target, is reached.

keywords:

pharmacokinetics, ciprofloxacin, continuous renal replacement therapy

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe